Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 2,270 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,270 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $14.00, for a total transaction of $31,780.00. Following the transaction, the chief financial officer owned 90,180 shares in the company, valued at $1,262,520. This represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, July 2nd, Raphi Levy sold 17,873 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.00, for a total transaction of $232,349.00.
• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The shares were sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Trading Up 2.6%

NASDAQ DRTS opened at $13.57 on Tuesday. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $14.11. The business has a 50 day moving average price of $9.96 and a 200-day moving average price of $7.97. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -20.25 and a beta of 1.17.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). As a group, equities analysts expect that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on DRTS. Piper Sandler lifted their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Citigroup lifted their price target on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Finally, LADENBURG THALM/SH SH increased their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $12.60.

Institutional Trading of Alpha Tau Medical

A number of institutional investors and hedge funds have recently modified their holdings of DRTS. Renaissance Technologies LLC purchased a new stake in shares of Alpha Tau Medical during the 1st quarter valued at $286,000. Principal Financial Group Inc. bought a new position in Alpha Tau Medical during the first quarter valued at about $132,000. Millennium Management LLC increased its holdings in Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after buying an additional 70,081 shares during the last quarter. Mariner LLC increased its holdings in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after buying an additional 1,915 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after acquiring an additional 17,500 shares during the period. 2.65% of the stock is owned by hedge funds and other institutional investors.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.